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1. Introduction 
Proliferation markers are among the most important biologic markers in the pathogenesis of 
many benign and malignant tumoral lesions and also some non-neoplastic diseases. 
Extensive studies have been conducted on this matter shedding light on the role of these 
markers in the pathogenesis of many of these lesions and their contribution to standard 
diagnostic protocols, determination of prognosis and even treatment monitoring of diseased 
cases.  
Cancer is among the major causes of morbidity and mortality worldwide. Determination 
and recognition of biomarkers that detect cancer in its early stages, monitor the disease 
progression or work as a specific marker for disease prognosis can boost our ability in 
confronting such conditions and improve cancer patients’ care by creating a personalized 
medicine for them.  Assessment of the cell growth or proliferative signature of tumoral 
lesions is among the main parameters in recognition of the biologic course of cancer, 
prognosis and evaluation of the treatment course.   
At present, we focus on recently introduced proliferative markers; MCM protein family, 
their basic biologic role and short review of the clinical application. 
2. Cell cycle and proliferative markers 
Cell proliferation is a precisely supervised process initiated and controlled by a large 
number of molecules and interrelated pathways.  Cell proliferation is induced and started 
by the act of growth factors. A controlled sequence of events take place sequentially for 
duplication and division of cell DNA during a process called cell cycle. The cell cycle 
consists of four distinct phases: G1 phase (pre-synthetic), S phase (DNA synthesis), G2 phase 
(premyotic) and M phase (mitosis). Quiescent phase or G0 is a resting phase where the cell 
has left the cycle and has stopped dividing (1). Replication of the genomic DNA should be 
completed before the onset of mitosis and is performed once in every cell cycle. 
Diagram of the cell cycle: 
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Several antigens are expressed during a cell cycle the oldest of which being Ki67 antigen. 
Some important antigens related to cell cycle were discovered later including PCNA, KiS2 
and MCM.  
Ki67 antigen was discovered by a German group of scientists (2) in early 1980s and 
identified by using mice monoclonal antibodies against a nuclear antigen from Hodgkin’s 
lymphoma cell line. This antigen is a non-histone protein. The name is derived from the city 
of origin (Kiel, Germany) and the number of the original clone in the 96-well plate (2). Ki67 
antigen has different expressions during various phases of cell cycle. Cells express this 
antigen in G1, S, G2 and M phases but they lack it in G0 phase. Concentration of Ki67 is low 
in G1 phase and reaches its peak during S phase. Ki67 is down-regulated during anaphase 
and telophase. Various studies on cell cycle analysis have shown that Ki67 antigen is not 
expressed in early G1 phase. Several antibodies are routinely being used for detection of 
Ki67 in paraffin embedded tissue samples using immunohistochemistry. At present, Ki67 
index score is routinely employed showing tumoral cells exhibiting nuclear staining. Use of 
Ki67 as a diagnostic and prognostic marker in many neoplasms has been extensively studied 
and its role in standard biological evaluation of the clinical course and management of 
cancers among them Lymphomas and breast cancers has been well recognized (3-6). 
MCM and cell cycle: 
Numerous proteins have been recognized to play a role in initiation of DNA replication 
which mainly include Origin Recognition Complex (ORC) and MCMs (7). Prokaryotes lack 
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MCM proteins and only eukaryotes possess this special type of molecules. However, some 




Fig. 1. Phylogenetic tree of eukaryotic MCMs, assembled using ClustalX (ftp://ftp-igbmc.u-
strasbg.fr/pub/ClustalX/) and Phylip 3.6 
(http://evolution.genetics.washington.edu/phylip.html) for Macintosh. Colors correspond 
to the seven MCM subfamilies. Dashed line, loose relationship. Accession numbers are as 
follows. S. pombe: SpMcm2, CAB58403; SpMcm3, P30666; SpMcm4, P29458, SpMcm5, 
CAA93299 and CAB61472; SpMcm6, CAB75412; SpMcm7, O75001. S. cerevisiae: ScMcm2, 
NP_009530; ScMcm3, NP_010882; ScMcm4, S56050; ScMcm5, A39631; ScMcm6, NP_011314; 
ScMcm7, S34027. Human: HsMcm2, P49736; HsMcm3, P25205; HsMcm4, NP_005905; 
HsMcm5, AAH03656; HsMcm6, NP_005906; HsMcm7, P33993; HsMcm8, NP_115874. 
Xenopus: Xmcm2, JC5085; Xmcm3, I51685; Xmcm4, T47223; Xmcm5, PC4225; Xmcm6Z, 
AAC41267; Xmcm6, T47222; Xmcm7, T47221. Arabidopsis: AtMcm2, NP_175112.1; AtMcm3, 
NP_199440.1; AtMcm4, NP_179236.2; AtMcm5, NP_178812.1; AtMcm6, NP_680393.1; 
AtMcm7, NP_192115.1; AtMcm8?, NP_187577.1; unknown Mcm, NP_179021.1. Drosophila: 
DmMcm2, AAF54207; DmMcm3, NP_511048.2; DmMcm4, S59872; DmMcm5, NP_524308.2; 
DmMcm6, NP_511065.1; DmMcm7, NP_523984.1. [11] 
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MCM proteins were first recognized in early 1980’s in Bik-Kwoon laboratory because of 
their role in maintenance of plasmids and mini chromosomes in Saccharomycess Cervisiae 
proliferative cells (11). 
The MCM protein family is named for the genetic screen in budding yeast from which the 
founding members were originally isolated. They were defective in minichromosome 
maintenance, showing a high rate of loss of plasmids that contained a cloned centromere 
and replication origin [12, 13]. 
These proteins play a role in the formation of prereplicative complex in G1 phase. By doing 
so, they license the chromatin for replication in the next phase of S (14). 
The MCM family of proteins is considered the key factor for initiation of replication 
regulation through cyclical DNA unwinding (14). Also, they play a role in condensation, 
cohesion, transcription and recombination (11). These proteins mainly include 6 major 
groups of MCM2 to MCM7 (11). In addition, 4 proteins of this family have been recognized 
to have independent function from the previously mentioned group including MCM1, 
MCM10, MCM8 and MCM9. It seems that the latter group of proteins only exists in multi-
cellular organisms and higher eukaryotes. 
Although MCM1 and MCM10 belong to this family name wise, they do not have much in 
common with MCM2-MCM7. MCM1 is a transcription factor and does not have a direct role 
in DNA replication (15, 16). 
MCM10 associates with MCM2-7 hexamer in the active replisome and helps to stabilize 
DNA polymerase -primase [Reviewed in 17]. 
MCM8 has been reported in vertebrates and Drosophila, but not in fungi and nematodes, 
and although it retains some sequence similarities in the Walker B and R-finger, its Walker 
A ATPase motif contains sequences more like the canonical ATPases. [18] Intriguingly, 
while human MCM8 shares all the classic MCM features including a putative zinc finger and 
the IDEKFM and arginine finger motifs, it is the only MCM that has a classic GKS motif in 
its Walker A sequence. It is widely expressed in a variety of tissues and may not be restricted 
to proliferating cells [19, 20]. The protein is found in the nucleus, apparently chromatin 
associated during S phase [19]. 
MCM9 is also found in similar organisms with the exception that it is missing in Drosophila, 
and it is unique to the family in that it lacks the carboxy-terminal ATPase domain including 
the Walker B motif. [18] MCM9 mRNA was up-regulated by transcription factor E2E1 and 
serum stimulation in NIH3T3 cells [21]. 
Various members of this family have been studied in all eukaryotes by genetic and 
biochemical methods and it has been demonstrated that MCM2-MCM7 proteins have been 
present in the genome of all the studied eukaryotes and have not been subject to gene loss or 
functional replacement during evolutionary diversification of eukaryotes. 
In Drosophila, MCM4 corresponds to the gene disc proliferation abnormal [22], while in 
Arabidopsis, MCM7 is PROLIFERA [23], stressing their role in cell division. Human MCM2 
(BM28) was first identified as a nuclear protein [24], and human MCM3 (P1) was isolated as 
a DNA polymerase alpha-associated protein [25]. 
Unusual MCMs 
Unusual MCMs have been recognized during the course of various studies. For example, at 
present it has been found that some yeasts possess MCM6. However, some variants i.e. the 
zygotic form of MCM6 have been detected in Xenopus. Also, some variants of MCM4 have 
also been found (26). It seems that these variants are a substitute for normal MCM when 
adequate growth conditions are met. 
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3. DNA replication and MCM2-7 family proteins 
Prior to DNA replication and during late M and G1 phases of the cell cycle, MCM2-7 form 
the pre-replication complex (pre-RC) by being loaded on to the origin recognition complex 
(ORC) at the origin of replication. This is activated at the G1-S transition of the cell cycle by 
the assembly of further protein components. [27] Only MCM2 and MCM3 have identifiable 
nuclear localization sequences (NLS), leading to an early suggestion that these MCMs 
provide nuclear targeting to the other members of the family [28]. In nearly all species, the 
bulk of MCMs are constitutively located in the nucleus throughout the entire cell cycle, with 
their chromatin association, rather than nuclear localization, subject to cell cycle regulation 
[24, 29-37]. However, there is still a role for the nuclear envelope in MCM complex assembly. 
This has been molecularly characterized using mutational analysis with the yeasts.  
MCM core is a trimeric complex that forms during purification in result of binding MCM4, 
MCM6, and MCM7 subunits tightly together. MCM2 binds to the core, but with decreased 
affinity. MCM3 and MCM5 form a dimer together and bind most weakly to the other 
MCMs, probably through MCM7 (Figure 2). [11] In the absence of other MCMs during in 
vitro reconstitution experiments, the MCM4,6,7 core will itself dimerize to form a dimer-
trimer (MCM4,6,7)2, which is disrupted by addition of MCM2 [38-40].  
All MCM members belong to the AAA+ ATPase family, which has a distinct ATPase 
domain that spans ~200 bases. This domain, referred to as the MCM box, consists of a 
Walker A ATPase motif, a Walker B ATPase motif, and an arginine finger motif (R-finger). 
Conserved sequences within the Walker B motif (IDEFDKM) and R-finger (SRDF) define the 
MCM family. Six of these members are conserved in all eukaryotes and form a 
heterohexameric complex known as MCM2-7, which has been studied extensively for its 
role in DNA replication. MCM2-7 is required for licensing and initiating origins of 
replication, and it acts during elongation as a helicase at the replication forks. Because of this 
function and studies in yeast, Arabidopsis and Drosophila, members of the MCM2-7 
complex, are thought to be essential [41]. 
The assessment of other multiple functions is consistent with studies in yeast, which showed 
that MCM proteins are far more abundant than would likely be required for the number of 
replication origins that exist, and this abundance cannot explain the fact that slight decreases 
in amounts of MCM proteins lead to the inability to complete S-phase and progress through 
the cell cycle [41]. 
Early data led to the identification of MCMs as central players in the initiation of DNA 
replication. More recent studies have shown that MCM proteins also function in replication 
elongation, probably as a DNA helicase. This is consistent with structural analysis showing 
that the proteins interact together in a heterohexameric ring. However, MCMs are strikingly 
abundant and far exceed the stoichiometry of replication origins; they are widely distributed 
on unreplicated chromatin. Analysis of MCM mutant phenotypes and interactions with 
other factors has now implicated the MCM proteins in other chromosome transactions 
including damage response, transcription, and chromatin structure. These experiments 
indicate that the MCMs are central players in many aspects of genome stability [11]. 
This family of proteins has been studied for interaction with other genes like Rb gene. 
4. MCM gene expression, DNA replication and Retinoblastoma gene 
Model showing RBR3 role in the RBR/E2F pathway controlling the expression of MCM2–7 
genes, DNA replication, and cell transformation. RepA inhibits RBR1; thus, stimulating the 
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pathway leading to S-phase gene expression, DNA synthesis, and cell transformation 
through up-regulation of RBR3. The transgenic approaches to down- or up-regulate RBR3 
are indicated in italics. The dotted line illustrates a potential inhibitory effect of RepA on 
RBR3 ruled out by Sabelli et al work[42]. 
 
 
Fig. 3.  
5. Expression of MCM protein family as a biological marker of proliferation in 
various diseases 
Genome of the MCM family is necessary for DNA replication and its role has been studied 
in various diseases and cancers. After the conduction of aforementioned basic studies, it was 
quickly revealed that this family of proteins not only can be considered as a cell proliferation 
marker but also can out-power previous classic factors of proliferation such as Ki67 because 
MCM expression in all phases of cell cycle. 
Parvaresh and colleagues (7) through cytometer analysis showed that number of cells 
expressing MCM6 in the proliferation phase was higher than those expressing Ki67 which 
was due to the expression of MCM6 at early G1 phase, a phase of cell cycle which does not 
express  Ki67 antigen. This study suggested that MCM6 may be a unique marker of cell 
cycle and might be employed as a novel prognostic marker for management of cancers.  
The following is the summary of studies on different members of this family: 
6. Clinicopathologic studies on expression of MCM family proteins as 
proliferative markers 
6.1 Expression of MCM family proteins in non neoplastic diseases 
DNA synthesis disorders and DNA damage response can also be important in pathogenesis 
of many non-neoplastic diseases. Since MCM family proteins play a major role in initiation 
of DNA synthesis and DNA damage response, evaluation of MCM subunits can be effective 
in recognizing the cause of various non neoplastic diseases.  
Cortez and colleagues showed that 2 MCM subunits namely MCM2-3 and MCM7 can be 
used as a check point for S phase considering their correlation with Ataxia-telangiectasia 
mutated (ATM) and ATM- and Rad3-related (ATR) and ATR-interacting protein (ATRIP)-
interacting subunit (43). 
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Evaluation of these factors has also helped in pathogenesis of Diabetes and some viral 
diseases.  
Willcox and coworkers (45) demonstrated that in type I diabetes Alpha and Beta cells 
undergo an increase in proliferation during progression.  These cells show a high level of co-
expression of Ki67 and MCM which are indicative of a proliferative response in an 
autoimmune attack during the course of diabetes type I. 
Qian and colleagues (44) showed that MCM complex can be effective in understanding the 
pathogenesis of many viral diseases.  Targeting MCM complex is one mechanism pUL117 
employs to help block cellular DNA synthesis during HCMV infection. Their finding 
substantiates an emerging picture that deregulation of MCM is a conserved strategy for 
many viruses to prevent host DNA synthesis and helps to elucidate the complex strategy 
used by a large DNA virus to moderate cellular processes to promote infection and 
pathogenesis. 
6.2 Role of MCM family proteins in neoplastic lesions 
Since classically proliferative biomarkers like Ki67 and proliferating cell nuclear antigen 
(PCNA) are known as the indices of proliferation phase, they are extensively used as 
diagnostic biomarkers in many types of cancers.  
Recently, MCM family proteins are a group of proteins that has been described in DNA 
replication in both benign and malignant tumors. As MCM proteins are only recognizable in 
cells which are in the cell cycle, therefore, it seems that they could be a better indicator of 
proliferative cells, cancer cells or malignant tissues compared to conventional biomarkers. 
Numerous studies has been suggested that their expression in some of the preneoplastic 
lesions and malignancies is often associated with a higher degree of cell atypia and poor 
prognosis.  
Up to our knowledge, expression of MCM family proteins has been extensively studied in 
neoplastic disorders including skin tumors, meningioma, non-small cell lung cancer, 
Hodgkin’s lymphoma [47], prostate cancer, oral tongue squamous cell carcinoma [48], 
chondrosarcoma, oligodendroglial tumors, esophageal neoplasm, renal cell carcinoma, 
colonic cancer, breast cancer, endometrial carcinoma, thyroid carcinoma, gastric 
adenocarcinoma, merckle cell carcinoma, cervical carcinoma and bladder carcinoma.  A 
summary of these studies is as follows: 
- Among skin tumors, squamous cell carcinoma, Bowen disease, basal cell carcinoma, 
malignant melanoma, and nevus have been studied (46). Also, Shin et al. reported a 
significant positive correlation between MCM2 immunoactivity and grade of actinic 
keratosis. They declared MCM2 as a reliable marker for diagnosis and grading and 
suggested further investigation on its prognostic value. 
- Shahjahan and associates [49] studied ProEx C, a biomarker reagent containing 
antibodies to minichromosome maintenance protein 2 (MCM2) and topoisomerase II A 
(TOP2A) used to detect aberrant S-phase induction in cells. The authors studied 289 
non-small cell lung cancers using immunohistochemistry and found ProEx C 
expression in more than two-thirds of the cancers and an association between strong 
expression and a longer 5-year survival in certain cellular subtypes. The findings 
suggested a role in tumor progression of these cancer cells and might be a potential 
basis for targeted therapy.  
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- Histomorphology and immunohistochemistry studies also showed increased 
expression of MCM2 in areas of malignant transformation in recurrent pleomorphic 
adenoma (50). 
- Nuclear expression of MCM2 has been demonstrated in a large number of breast cancer 
patients. Its expression in dysplastic, malignant and cancer cells can be predictive of 
potential malignancy and can help in determining the grade of breast cancer (51, 52). 
- Expression of MCM3 has been evaluated in astrocytic tumors and cervical carcinoma 
(53). 
- High expression of MCM4 has been reported in meningioma and cervical carcinoma 
(52, 54).  
- Also, MCM4 may play an essential role in the proliferation of some NSCLC cells. Taken 
together with higher expression in NSCLCs and its correlation with clinicopathologic 
characteristics such as non-adenocarcinoma histology, MCM4 may have potential as a 
therapeutic target in certain population with NSCLCs [55, 56].  
- Increased expression of MCM4 might be associated with pathological staging of 
esophageal cancer [57].  
- MCM5 expression has been shown in hepatitis induced carcinogenesis (58), 
adenocarcinoma of the stomach (59), and meningioma (60). Co-expression of MCM2 
and MCM5 as a marker of proliferation and differentiation has been evaluated in colon 
cancer.  High expression of these two in mild and moderate cutaneous dysplasia in 
proliferative lesions of verrucous leukoplakia can help in studying the prognosis of 
their malignant transformation. Despite the expression of MCM4 and MCM5, increased 
expression of MCM6 and MCM7 has also been studied in meningioma (54). 
- A study showed that expression of MCM7 in esophageal squamous cell carcinoma was 
associated with a more invasive nature (61). 
- Aberrant over-expression of proteins called minichromosome maintenance (MCM) 
proteins at the mucosal surface of dysplastic esophageal squamous epithelium and 
Barrett's mucosa may indicate proliferation potential. [62]  
- MCM7 detected more cells in the cycle than Ki67 and PCNA and all cases of SC 
glioblastoma, the most aggressive subset, displayed a significant increase of MCM7-
stained nuclei versus those stained with Ki67. [63] These studies implicate MCM7, and 
the DNA replication licensing gene family, in prostate cancer progression, growth and 
invasion. [64] MCM-7 also has been studied in gestational trophoblastic disease [65] and 
metastatic colon carcinoma [66]. 
- In previous studies such as in Fujioka et al [67] study they demonstrated that higher 
levels of MCM 7 expression were correlated with poor differentiation of tumors, non-
bronchioloalveolar carcinomas of lung, large tumor size and poor prognosis. Li et al 
[68] also showed that MCM 7 expression was significantly correlated with poor 
histologic grade, old age, and poor survival in cases of endometrial carcinoma. 
Padmanabhan et al [69] revealed that MCM 7 was associated with tumor stage and 
perineural invasion in prostatic intraepithelial neoplasia and invasive adenocarcinoma.  
6.3 The role of MCM protein family in cancer treatment 
Because of MCM family proteins’ vital role in genome duplication in proliferating cells, 
deregulation of the MCM function results in chromosomal defects that may contribute to 
tumorigenesis. As we already reviewed, the MCM proteins are highly expressed in 
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malignant human cancers cell and pre-cancerous cells undergoing malignant 
transformation. They are not expressed in differentiated somatic cells that have been 
withdrawn from the cell cycle. Therefore, these proteins are ideal diagnostic markers for 
cancer and promising targets for anti-cancer drug development. [70) 
In this respect, medications targeting some members of the MCM family are considered 
novel anticancer drugs.  
Two studies evaluated the role of medications in management of the tumor in prostate 
cancer patients by measuring the expression of MCMs.  In one of these studies due to the 
high level of MCM expression in these lesions Genistein and Trichostatin (TSA) were 
administered resulting in down-regulation of all MCM genes and subsequently decreasing 
the S phase in tumoral cells of the prostate cancer (54). 
Iljin et al, (71) in their study indicated that three novel cancer selective growth inhibitory 
compounds can result in decreased DNA synthesis. This reduction can be evaluated via 
MCM expression.  
7. Conclusion 
Members of the MCM family play a key role as the initiator of DNA replication working as 
DNA helicase. They are also involved in the process of transcription, cohesion, 
condensation, and recombination in both the nucleus and the cytoplasm.  These markers 
have been extensively evaluated in basic and clinical studies. Aforementioned clinical 
studies showed the expression of these proteins specially MCM 2, 3,4,5,6,7 specially in 
preneoplastic and cancers and also in some viral and endocrine diseases eg Diabetes .  They 
have been suggested as standard diagnostic and prognostic biomarkers in some tumoral 
lesions.  
Many of these proteins can be employed as a target for anti-cancer medications currently 
present in the market or those under development.  
Further studies on various members of this family in all the pathologic diseases specially 
precancerous lesions and malignant processes  can illuminate their  pathogenesis and 
biologic behavior  . In tumoral lesions, these markers can be easily evaluated through 
immunohistochemistry. Therefore, it is recommended that research projects focus on 
studying not only one of them but evaluation co expression of some of the various members 
of this family in tumoral, pre-neoplastic and neoplastic lesions in all organs.In this way, 
these proliferative markers can gradually substitute the standard proliferative index 
markers like Ki67 which was the main objective of the present review.  
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